Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Imprimis Pharmaceuticals Inc.

www.imprimispharma.com

Latest From Allergan PLC

2Q Pharma Results Preview: Lilly, Biogen, Amgen, GSK And Gilead

Part two of Scrip's preview of first quarter earnings: product launches, management priorities, pricing strategies and biosimilar competition are key themes at the half-year mark.

Sales & Earnings Business Strategies

UK Court Shakes Up Test For Equivalent Infringement In Lilly/Actavis Case

The UK Supreme Court has shaken up the test for equivalent infringement in the UK, which is good news for patent owners out to catch infringers.

BioPharmaceutical Generic Drugs

Biosimilarity Margin Change By FDA Might Give Amgen's Avastin Copy Big Head Start

Did Amgen/Allergan get a lucky break by already having their clinical trial enrolled and being unable to increase the sample size for their Avastin biosimilar?

Biosimilars Advisory Committees

Freshly Funded Symic Bio Plays In The Matrix

Emerging Company Profile: Symic Bio recently raised $30m in a Series B financing. CEO Ken Horne talks about the firm's therapeutic focus on the body's extracellular matrix as a therapeutic target, and its two lead programs in peripheral vein graft failure prevention and knee osteoarthritis.

StartUps and SMEs Companies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
      • Topical Delivery
  • Therapeutic Areas
  • Gynecological, Urological
  • Neurology, Nervous System
  • Ophthalmic
  • Otolaryngology
  • Alias(es)
  • Transdel Pharmaceuticals Inc.
  • Trans-Pharma Corp.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Imprimis Pharmaceuticals Inc.
  • Senior Management
  • Mark L Baum, CEO
    Andrew R Boll, CFO
    Gary Seelhorst, VP, Bus. Dev.
    John Saharek, Chief Commercial Officer
  • Contact Info
  • Imprimis Pharmaceuticals Inc.
    Phone: (844) 446-6979
    12264 El Camino Real
    Ste. 350
    San Diego, CA 92130
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register